Lomaira (Phentermine 8 mg): Average Weight Loss, How It Differs From Adipex-P 37.5 mg, and When TID Dosing Wins (2026)

Lomaira is phentermine HCl 8 mg dosed three times a day, half an hour before meals — the FDA-approved divided-schedule low-dose alternative to Adipex-P 37.5 mg once daily. Both drugs are the same active ingredient (phentermine hydrochloride), both DEA Schedule IV, both labeled as a short-term (a few weeks, typically up to 12 weeks) adjunct to diet and exercise in management of exogenous obesity. Average weight loss with Lomaira tracks the broader phentermine-class average of roughly 5-7% of baseline body weight at 12-26 weeks per the published phentermine pharmacotherapy literature (Bray GA et al., Lancet 2016, PMID 26868660; Hendricks EJ et al., Int J Obes 2014, PMID 23736363). The TID 8-mg schedule is positioned for peak-trough smoothing, finer dose control, and tolerability in patients sensitive to once-daily 37.5 mg — NOT as a higher-total-daily-dose alternative. Below: verbatim FDA labels for both drugs, the TID-vs-QD rationale, average weight loss expectations, side effects, contraindications, DEA Schedule IV considerations, and when 8 mg TID actually beats 37.5 mg QD.

What is Lomaira?

Lomaira is a brand-name oral tablet containing phentermine hydrochloride 8 mg, manufactured by KVK-Tech, Inc. The FDA application is ANDA 203495 (Abbreviated New Drug Application — meaning it was approved by demonstrating bioequivalence to the original phentermine reference product, not by submitting a new NDA). It is dispensed as scored 8-mg tablets, allowing half-tablet (~4 mg) administration if needed for tolerability titration. Phentermine itself has been FDA-approved as a weight-loss drug since 1959.

The molecule — phentermine — is a sympathomimetic amine anorectic. It works primarily by stimulating norepinephrine release in the central nervous system, which suppresses appetite. It is chemically related to amphetamine (a Schedule II controlled substance) but has substantially less abuse potential — it is classified by the DEA as Schedule IV, the same schedule as alprazolam (Xanax) or diazepam (Valium).

FDA-approved indication (verbatim from §1)

Per the Lomaira DailyMed label §1 INDICATIONS AND USAGE, Lomaira is indicated as:

“a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) ≥30 kg/m², or ≥27 kg/m² in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).”

The §1 indication for Adipex-P is materially identical — the same short-term, adjunct, BMI-thresholded, exogenous-obesity framing. This is the single most important YMYL fact about both drugs: phentermine is FDA-labeled for a few weeks of use, NOT for chronic weight management. The 12-week limit is a clinical convention drawn from the original short-term efficacy trials. Off-label long-term phentermine prescribing does occur (some prescribers continue patients past 12 weeks based on individual benefit-risk assessment), but that is off-label use and is not what the FDA approved.

Dosing — Lomaira (verbatim §2)

Per the Lomaira DailyMed label §2 DOSAGE AND ADMINISTRATION:

“The recommended dose of LOMAIRA is one tablet three times a day half hour before meals. Dosing should be individualized to obtain an adequate response with the lowest effective dose. Late evening administration should be avoided because of the possibility of resulting insomnia.”

Three concrete points about the Lomaira schedule:

• Three times a day, half an hour before meals. The TID schedule maps appetite suppression onto each eating event, rather than concentrating it at breakfast.
• One 8-mg tablet per dose × 3 doses = 24 mg/day total. That is less than Adipex-P's 37.5 mg/day total — but the labels do not equate the two on a total-daily-dose basis. There is no FDA-published "dose-equivalence" conversion between Lomaira 8 mg TID and Adipex-P 37.5 mg QD.
• Late evening administration should be avoided. The third dose should still be early enough that the stimulant effect does not interfere with sleep — typically before mid-afternoon for most patients.

The tablet is scored, allowing half-dose (~4 mg) titration for patients with sympathomimetic side effects (heart-rate elevation, blood-pressure elevation, jitteriness) at the full 8-mg dose.

Dosing — Adipex-P (verbatim §2)

Per the Adipex-P DailyMed label §2 DOSAGE AND ADMINISTRATION for adults and pediatric patients 17 years of age and older:

“The recommended dose of Adipex-P is one capsule (37.5 mg) or one tablet (37.5 mg) daily, taken before breakfast or 1 to 2 hours after breakfast. Dosing should be individualized to obtain an adequate response with the lowest effective dose. Late evening administration should be avoided because of the possibility of resulting insomnia.”

The Adipex-P 37.5 mg tablet is also scored, so a prescriber who wants a lower starting dose without switching to Lomaira can write 18.75 mg (half-tablet) once daily. Many prescribers in practice start at 18.75 mg QD on the Adipex-P side and titrate up only if needed.

Why TID dosing? Peak-trough smoothing and tolerability

Phentermine has a relatively long elimination half-life (~20 hours) but its peak sympathomimetic effect is concentration-driven — heart-rate elevation, blood-pressure elevation, anxiety, and insomnia track the post-dose peak more than the trough. A single 37.5 mg morning dose produces a high peak concentration in the first few hours; for tolerability-sensitive patients, that peak is the limiting factor.

Lomaira's 8 mg TID schedule does three useful things:

• Lower per-dose peak. The 8-mg dose produces a smaller post-dose concentration spike than 37.5 mg, reducing peak-driven sympathomimetic side effects.
• More even appetite-suppression coverage across the eating day. Patients who overeat at lunch and dinner (not just breakfast) get a fresh dose 30 minutes before each meal, rather than relying on the tail of a morning dose.
• Finer dose-titration granularity. A prescriber can write Lomaira 8 mg BID (~16 mg/day), 8 mg TID (24 mg/day), 4 mg TID (12 mg/day) using the scored tablet, or escalate from 4 mg to 8 mg per dose individually — substantially more flexibility than the 37.5 mg / 18.75 mg binary on the Adipex-P side.

These positioning rationales come from the package labeling and from the published phentermine pharmacotherapy literature — they are not a head-to-head clinical trial finding. There is no published RCT demonstrating that Lomaira 8 mg TID produces measurably less peak-driven side effects than Adipex-P 37.5 mg QD; the positioning is pharmacokinetic and clinical-practice rationale, not RCT-proven superiority.

Lomaira vs Adipex-P — side-by-side

The single most important takeaway from this table is the NO FDA-published dose-equivalence line. Patients sometimes assume that "less total milligrams = weaker drug = less weight loss" — that is the wrong framing. Lomaira's TID schedule is positioned for tolerability, not for delivering a lower effective anorectic dose. Whether 24 mg/day TID produces equivalent, more, or less average weight loss than 37.5 mg/day QD has not been studied head-to-head in a published RCT.

Average weight loss with Lomaira

There is no large randomized controlled trial of Lomaira specifically that establishes a single average-weight-loss number — Lomaira was approved as an ANDA, meaning the sponsor demonstrated bioequivalence to the original phentermine reference, not new efficacy. The clinical expectation for Lomaira is therefore the phentermine-class average, taken from the broader published literature on phentermine monotherapy for weight loss.

Per the Bray et al. 2016 Lancet review “Management of obesity” (PMID 26868660), short-term phentermine monotherapy is associated with mean placebo-adjusted weight loss of approximately 3-5 kg over 12 weeks in adults with obesity — corresponding to roughly 5% of baseline body weight in the trial populations. The Hendricks et al. 2014 Int J Obes analysis (PMID 23736363), which examined phentermine prescribed during long-term obesity treatment, documented sustained weight loss in clinical-practice cohorts at 6-12 months on continued phentermine; this is off-label long-term use, not the FDA-approved short-term indication.

A reasonable, label-aligned expectation for Lomaira at 12-26 weeks of adherent use, combined with a reduced-calorie diet and increased physical activity:

• Average: ~5-7% of baseline body weight at 12-26 weeks. For a 200 lb patient, that is roughly 10-14 lb.
• High responders (heuristically the top quartile in clinical practice): 8-12% of baseline body weight at 26 weeks.
• Non-responders / low responders: less than 3% weight loss at 12 weeks. Per the FDA label, if a patient has not lost meaningful weight after 12 weeks on phentermine, the drug is unlikely to produce additional benefit and continuation should be reconsidered.

This puts Lomaira (and phentermine monotherapy in general) well below modern GLP-1 effect sizes: Wegovy at 2.4 mg semaglutide produces ~14.9% mean weight loss at 68 weeks (STEP-1 trial), Zepbound at 15 mg tirzepatide produces ~20.9% at 72 weeks (SURMOUNT-1). Phentermine's appeal in 2026 is not effect size — it is oral, low-cost, no GLP-1 GI side effects, and accessible without REMS.

Lomaira side effects (verbatim §6)

Per the Lomaira DailyMed label §6 ADVERSE REACTIONS, the most common adverse reactions are:

“Cardiovascular: primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events. Central Nervous System: overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis. Gastrointestinal: dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Allergic: urticaria. Endocrine: impotence, changes in libido.”

In clinical practice, the dominant tolerability issues are dry mouth, insomnia, palpitations / heart-rate elevation, and blood-pressure elevation. The FDA label also includes specific warnings about:

• Primary pulmonary hypertension — a rare but serious adverse event historically associated with combination phentermine + fenfluramine therapy ("phen-fen"). Phentermine monotherapy carries this label warning even though the strong evidence base links pulmonary hypertension to combinations or to longer durations.
• Valvular heart disease — same historical phen-fen context. Patients with known heart-valve disease should not take phentermine.
• Tolerance / loss of effect within a few weeks — the label notes that tolerance to the anorectic effect usually develops within a few weeks. This is one of the rationales for the short-term FDA indication.

Contraindications (verbatim §4)

Per the Lomaira DailyMed label §4 CONTRAINDICATIONS, Lomaira is contraindicated in patients with:

“History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension); during or within 14 days following the administration of monoamine oxidase inhibitors (MAOI); hyperthyroidism; glaucoma; agitated states; history of drug abuse; pregnancy; nursing; known hypersensitivity, or idiosyncrasy to the sympathomimetic amines.”

Three of these contraindications deserve emphasis:

• Pregnancy. Phentermine is contraindicated in pregnancy. Patients of reproductive potential should have a documented pregnancy plan and effective contraception before starting. If pregnancy is confirmed during treatment, phentermine must be discontinued immediately.
• MAOI use within 14 days. Co-administration with MAOIs (selegiline, phenelzine, tranylcypromine, isocarboxazid, linezolid) can cause hypertensive crisis. A 14-day washout is mandatory in either direction (starting phentermine after stopping MAOI, or starting MAOI after stopping phentermine).
• History of drug abuse. Phentermine is a DEA Schedule IV controlled substance. Patients with a documented history of stimulant or substance use disorder are contraindicated.

DEA Schedule IV considerations and the Ryan Haight Act

Phentermine — including both Lomaira and Adipex-P — is a DEA Schedule IV controlled substance. Schedule IV scheduling has three concrete consequences for prescribing:

1. Federal Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (Public Law 110-425) regulates how Schedule IV substances may be prescribed via telehealth. Historically a Ryan Haight-compliant phentermine prescription required at least one in-person patient evaluation by the prescriber. The DEA's COVID-era telemedicine flexibilities — extended through 2026 by subsequent rulemaking — temporarily relax this for many telehealth platforms, but the framework still applies and the post-flexibility rules remain unsettled.
2. Refills are limited to 5 within 6 months. A Schedule IV prescription cannot be refilled indefinitely — after 5 refills or 6 months from the original prescription date (whichever comes first), a new prescription is required. This naturally aligns with the short-term FDA indication.
3. State pharmacy regulations layer on top. Some states have additional restrictions on phentermine prescribing (limits on duration of therapy, BMI thresholds stricter than the FDA label, specialist-only prescribing). State variation is substantial — a patient who can get phentermine via telehealth in one state may not be able to in another.

For the full prescribing-pathway framework — including which telehealth platforms are Ryan Haight-compliant for Schedule IV — see our how to get phentermine online (FDA-approved telehealth pathways) guide.

When Lomaira (8 mg TID) makes sense — and when Adipex-P (37.5 mg QD) does

These positioning calls are pharmacokinetic + clinical-practice reasoning, not RCT evidence — there is no head-to-head trial comparing Lomaira to Adipex-P. Use them as a framework, not a protocol; the actual prescribing decision belongs with your prescriber.

Patient profiles where Lomaira (8 mg TID) is positioned to win

• Sympathetic-side-effect-sensitive patients — patients who tried generic phentermine 37.5 mg or Adipex-P 37.5 mg and could not tolerate the heart-rate elevation, blood-pressure elevation, jitteriness, or headache from the morning peak.
• Patients with controlled hypertension where the prescriber wants to minimize peak blood-pressure excursions while still using phentermine for the obesity comorbidity. (Note: uncontrolled hypertension is a label contraindication for phentermine in any form.)
• Patients who overeat at lunch and dinner, not just breakfast — the TID schedule places appetite suppression closer to each eating event.
• Patients who need finer dose-titration granularity — using 4 mg per dose (half a scored tablet), a prescriber can write 4 mg BID, 4 mg TID, 8 mg + 4 mg + 4 mg, or any other low-dose pattern that 37.5 mg / 18.75 mg on the Adipex-P side cannot match.
• Patients restarting phentermine after a tolerability failure on once-daily 37.5 mg, where the prescriber wants to retry phentermine at a lower-impact schedule before abandoning the drug class.

Patient profiles where Adipex-P (37.5 mg QD) is positioned to win

• Patients prioritizing cost — generic phentermine 37.5 mg is ~$9-30/month at retail pharmacies; brand Lomaira is ~$60-150/month. For a short-term (≤12-week) FDA-labeled course, the cost difference can dominate.
• Patients prioritizing dosing simplicity — once-daily, before-breakfast dosing is easier to adhere to than three-times-daily, half-hour-before-each-meal dosing. Adherence drops with TID schedules in real-world practice.
• Patients who tolerate 37.5 mg fine and don't need the peak-trough smoothing.
• Patients whose primary appetite challenge is at breakfast / morning — a single AM dose covers the eating day adequately for some patients.

Lomaira vs Qsymia (with topiramate) — when combination beats monotherapy

Qsymia is the FDA-approved fixed-dose combination of phentermine + topiramate ER (NDA 022580, Vivus, DailyMed SetID 40dd5602-53da-45ac-bb4b-15789aba40f9). Topiramate is an anticonvulsant whose appetite-suppressing side effect was leveraged into a fixed-dose anti-obesity combination. Qsymia produces materially larger average weight loss than phentermine monotherapy:

• Phentermine monotherapy (Lomaira or Adipex-P): ~5-7% mean body-weight loss at 12-26 weeks.
• Qsymia 7.5/46 mg (recommended dose): ~7.8% mean body-weight loss at 56 weeks (CONQUER, Lancet 2011).
• Qsymia 15/92 mg (top dose): ~9.8% mean body-weight loss at 56 weeks (CONQUER); ~10.5% at 108 weeks (SEQUEL).

When does Qsymia beat Lomaira? When the patient needs more weight loss than phentermine monotherapy can deliver, tolerates topiramate, is not pregnant or planning pregnancy (Qsymia carries a topiramate-driven REMS for fetal cleft lip / cleft palate risk), and can navigate getting a Qsymia prescription dispensed at a REMS-certified pharmacy. When does Lomaira beat Qsymia? When the patient cannot tolerate topiramate (paresthesia, cognitive blunting, kidney stone risk, taste alteration), wants a less restrictive REMS-free pathway, or wants to start with the simpler monotherapy and escalate only if needed. Full Qsymia evidence base in our Qsymia phentermine + topiramate evidence deep-dive; the topiramate-specific evidence is in our Topamax / topiramate for weight loss article.

Lomaira + GLP-1 stack questions

Patients on a GLP-1 (Wegovy, Zepbound, Foundayo, Saxenda, Mounjaro, Ozempic) sometimes ask whether they can add Lomaira on top — typically when GLP-1 weight loss has plateaued or the response is below average. The honest answer is:

• The phentermine + GLP-1 combination is off-label. There is no FDA-approved combination indication for phentermine + a GLP-1.
• The combination is not RCT-tested in any large randomized trial. The evidence base is observational and single-clinic case series.
• Cardiovascular risk is the dominant safety concern. Phentermine alone elevates heart rate and blood pressure; GLP-1s typically lower both. The net cardiovascular effect of the combination has not been characterized in large prospective trials.
• The combination should only be used under specialist oversight (obesity medicine specialist, endocrinologist, or cardiologist comfortable with the combination), with baseline and on-treatment cardiovascular monitoring.

Full discussion of the phentermine + GLP-1 stack in our Can you take phentermine with a GLP-1? article. As with any combination obesity-pharmacotherapy decision, this belongs with your prescriber, not a telehealth screener.

Bottom line

• Lomaira is FDA-approved phentermine HCl 8 mg, dosed three times a day half an hour before meals. ANDA 203495 (KVK-Tech). DailyMed SetID cde9fb09-e5af-434d-8874-e4f9f974d893. NOT NDA 208407 — that is a common online error.
• Adipex-P is FDA-approved phentermine HCl 37.5 mg, dosed once daily before breakfast. ANDA 085128 (Teva). DailyMed SetID f5b2f9d8-2226-476e-9caf-9d41e6891c46.
• Both are DEA Schedule IV phentermine, both labeled for short-term (a few weeks, typically up to 12 weeks) adjunct use to diet and exercise in management of exogenous obesity.
• The FDA labels do NOT equate Lomaira 24 mg/day TID with Adipex-P 37.5 mg/day QD. Lomaira's TID schedule is positioned for tolerability and finer dose control, not as a lower-total-dose substitute. There is no head-to-head RCT comparing the two.
• Average weight loss with phentermine monotherapy is ~5-7% of baseline body weight at 12-26 weeks, well below modern GLP-1 effect sizes (Wegovy ~14.9%, Zepbound ~20.9%). Phentermine's appeal in 2026 is oral, low-cost, GLP-1-side-effect-free, and REMS-free — not effect-size-leading.
• Lomaira (8 mg TID) is positioned to win for sympathetic-side-effect-sensitive patients, controlled hypertension, fine-titration needs, and patients restarting phentermine after a 37.5 mg tolerability failure.
• Pregnancy, MAOI use within 14 days, hyperthyroidism, glaucoma, history of cardiovascular disease, agitation, and history of drug abuse are contraindications for both Lomaira and Adipex-P.
• The decision between Lomaira, Adipex-P, generic phentermine 37.5 mg, Qsymia, or a GLP-1 belongs with your prescriber. This article is the FDA-label evidence base, not a prescribing recommendation.

Related research and tools

• How to get phentermine online (FDA-approved telehealth pathways) — Ryan Haight Act and legitimate prescribing pathways for DEA Schedule IV phentermine
• Qsymia (phentermine + topiramate) evidence deep-dive — CONQUER / EQUIP / SEQUEL phase 3 efficacy + the REMS framework
• Can you take phentermine with a GLP-1? — off-label combination therapy considerations
• Topamax / topiramate for weight loss — the topiramate-specific evidence including the fetal-toxicity REMS rationale
• Best appetite suppressant 2026 — how phentermine ranks against the modern GLP-1s and other oral options
• GLP-1 pricing index — full cash-pay and insurance-plus-copay-card pricing across the FDA-approved AOM landscape
• FDA-approved weight loss medications hub — the master directory
• GLP-1 BMI calculator — check the FDA-label BMI threshold (≥30, or ≥27 with a weight-related comorbidity) that gates eligibility for phentermine and the GLP-1s alike

Important disclaimer. This article is educational and does not constitute medical advice or a recommendation for or against any specific phentermine product. Phentermine (Lomaira, Adipex-P, generic) is a DEA Schedule IV controlled substance with significant contraindications and is FDA-labeled only for short-term adjunct use. The decision to start, continue, or discontinue phentermine — and the choice between Lomaira 8 mg TID and Adipex-P 37.5 mg QD — is a clinical judgment that belongs with a qualified prescriber who has full knowledge of your medical history, cardiovascular risk profile, current medications, and pregnancy plans. If you develop chest pain, severe headache, marked blood-pressure elevation, shortness of breath, or new psychiatric symptoms on phentermine, contact your prescriber or seek emergency care.